In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Calmare Therapeutics Inc. (OTCMKTS:CTTC) reported that Yarbro Stan has picked up 133,242 of common stock as of 2017-06-30.
The acquisition brings the aggregate amount owned by Yarbro Stan to a total of 133,242 representing a 0.46% stake in the company.
For those not familiar with the company, Calmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company’s technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company’s subsidiary is Vector Vision, Inc.
A glance at Calmare Therapeutics Inc. (OTCMKTS:CTTC) key stats reveals a current market capitalization of $2.51 Million based on $28.79 Million shares outstanding and a price at last close of $0.100 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-09-27, Hornidge picked up 2,500 at a purchase price of $0.59. This brings their total holding to 103,365 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Calmare Therapeutics Inc. (OTCMKTS:CTTC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.